Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Common Equity (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Common Equity data on record, last reported at $171.2 million in Q3 2025.

  • For Q3 2025, Common Equity rose 274.09% year-over-year to $171.2 million; the TTM value through Sep 2025 reached $171.2 million, up 274.09%, while the annual FY2024 figure was $44.0 million, 196.99% up from the prior year.
  • Common Equity reached $171.2 million in Q3 2025 per ABEO's latest filing, up from $163.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $171.2 million in Q3 2025 and bottomed at -$8.9 million in Q1 2024.
  • Average Common Equity over 5 years is $51.1 million, with a median of $41.4 million recorded in 2025.
  • The widest YoY moves for Common Equity: up 683.75% in 2024, down 147.39% in 2024.
  • A 5-year view of Common Equity shows it stood at $42.4 million in 2021, then crashed by 36.84% to $26.8 million in 2022, then plummeted by 44.6% to $14.8 million in 2023, then skyrocketed by 196.99% to $44.0 million in 2024, then surged by 288.89% to $171.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $171.2 million in Q3 2025, $163.6 million in Q2 2025, and $41.4 million in Q1 2025.